Continued investigation of ER fusion proteins both in IDC-NST and ILC contexts may provide alternate treatment regimens in patients diagnosed with endocrine-resistant breast cancer, an acutely relevant endeavor in the setting of updated guidelines to identify ER mutants during therapeutic intervention (73). Here, ESR1 is linked to breast carcinoma.